1. Biomarkers and surrogate end points—the challenge of statistical validation
2. Biomarkers—A General Review
3. The perils of surrogate endpoints
4. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics.https://www.fda.gov/media/71195/download.
5. Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease;Budd Haeberlein S;J Prev Alzheimers Dis,2022